Subject: New Client EDXC Issues Strong Results for Fiscal Q1 2018

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
New Client EDXC Issues Strong Results for Fiscal Q1 2018
Hot Stock to WatchHot Stock to Watch

Company: Endexx Corporation (Pink Sheets: EDXC)


Price: 0.0713

Change (%): - 0.0028 (3.72)

Volume: 253,519
EDXC Chart
Endexx Reports Another Record-Breaking Quarter for Fiscal Q1 2018

Company sees revenues up 123% year over year and up 32% quarter over quarter

CAVE CREEK, AZ, Feb. 16, 2018 (GLOBE NEWSWIRE) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, is pleased to report record sales growth for its first quarter of fiscal 2018. For the three months ended December 31, 2017, the company generated $192,000 in sales, representing a 32% sequential quarterly increase and a year-over-year revenue growth of 123 percent.

First Quarter 2018 Milestones and Updates:

  • Endexx acquired Holistic Earth Remedies LLC for its best-selling topical pain relief products.
  • The company was awarded “Best Advancements in Hemp Industry” at Uptick Newswire’s Uppie Awards.
  • Endexx exhibited and demoed at booth 420 at the 3rd Annual Southwest Cannabis Conference & Expo in Phoenix.
  • Endexx sponsored “Athletes for Care” at the 4th Annual Cannabis World Congress and Business Exposition.
CEO Todd Davis commented, “Our first quarter was another record-breaking quarter, which was over 100% increase over the first quarter of 2017 in our core revenues. During that time, we successfully acquired Holistic Earth Remedies, adding an additional $23,423 in revenues for our Q1. We also attended a few conferences to raise awareness of our line of products and our brand. The quarter brought a significant increase in sales from our precisely formulated topical cannabidiol (CBD) balm and mist, along with our travel sleep aid, teas, oils, capsules, soft chews for dogs and other products that provide key benefits to the user. More recently, we are extremely excited by our contract with Impulse Health to bring retail products and our AutoSpense™ industrial-grade automated inventory control and dispensing solutions into the OTC pharmacy market. This immediately provides Endexx a focused pathway into 20,000 retail and pharmacy locations nationwide utilizing our proprietary technology. This is a fantastic opportunity for us – one that we will reap rewards from the next five years, and many times over.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks